Since November 2023, Oakleaf Contracts has been delivering our scope on one of Europe’s most significant biopharmaceutical manufacturing expansions, and we are proud to confirm completion of our section of works.
Denmark continues to lead the way in advanced biologics production. When this campus completes in 2026, it will stand among Europe’s largest end-to-end cell culture CDMO facilities, incorporating 20 x 20,000L bioreactors and integrated drug product capability.
Against that backdrop, Oakleaf has delivered:
▪ 30,000m²+ of Knauf drywall systems
▪ 48 alternative wall types across complex regulated environments
▪ 5,000+ openings coordinated with MEP and specialist trades
▪ 350+ Quality Inspections successfully achieved
▪ Delivered across 4 zones, 3 levels, 2 adjoining buildings
▪ Completed within a 24-month programme
All executed within a live, fast-track advanced manufacturing environment alongside leading international partners including Ardmac, Jones Engineering, Firesafe, Mercury, Jakon, Bravida and Zauner.
This was not standard drylining.
It required:
• Cleanroom-grade precision
• Intensive QA documentation and compliance control
• Integrated programme and commercial management
• Detailed sequencing with multinational trade interfaces
• Relentless health & safety leadership
Most importantly – it required people. Our Denmark-based team demonstrated resilience, discipline and technical excellence throughout. Operating within a development shaped by strong sustainability commitments and long-term life science investment, Oakleaf has proven its capability in complex pharmaceutical environments at European scale.
We are proud of what the team has achieved and we are ready for what comes next.
LifeSciences PharmaConstruction AdvancedManufacturing Cleanroom